title: Extending outpatient medical abortion services through 70 days of gestational age.
abstract: OBJECTIVE
  To estimate the efficacy and acceptability of medical abortion at 64-70 days from last menstrual period (LMP) and to compare it with the already proven 57-63 days from LMP gestational age range.
  
  
  METHODS
  This prospective, comparative, open-label trial enrolled 729 women with pregnancies 57-70 days from LMP requesting abortion at six U.S. clinics. Medical abortions were managed with 200 mg mifepristone and 800 micrograms buccal misoprostol and sites' service delivery protocols. Follow-up visits occurred 7-14 days after mifepristone, with an abortion considered complete if surgical intervention was not performed. Success, ongoing pregnancy, and acceptability rates were compared.
  
  
  RESULTS
  A total of 629 cases were analyzable for efficacy. Success rates were similar in the two groups (57-63 days group: 93.5%, 95% confidence interval [CI] 90-96; 64-70 days group: 92.8%, 95% CI 89-95). Ongoing pregnancy rates also did not differ significantly (57-63 days: 3.1%, 95% CI 1.6-5.8; 64-70 days: 3.0%, 95% CI 1.5-5.7). Acceptability was high and similar in both arms, with most women (57-63 days: 87.4%; 64-70 days: 88.3%) reporting that their experience was either very satisfactory or satisfactory.
  
  
  CONCLUSIONS
  Medical abortion with mifepristone and misoprostol in current outpatient settings is an efficacious and acceptable method of ending pregnancies 64-70 days from LMP and can be offered without alteration of existing services.
  
  
  BACKGROUND
  clinicaltrials.gov, www.clinicaltrials.gov, NCT00997347.
  
  
  METHODS
  II.
authors.affiliation: Gynuity Health Projects, Planned Parenthood of New York City, and the Columbia University College of Physicians and Surgeons, Obstetrics/Gynecology Department, New York, New York 10010, USA.
authors.forename: Beverly
authors.initials: B
authors.lastname: Winikoff
authors.forename: Ilana G
authors.initials: IG
authors.lastname: Dzuba
authors.forename: Erica
authors.initials: E
authors.lastname: Chong
authors.forename: Alisa B
authors.initials: AB
authors.lastname: Goldberg
authors.forename: E Steve
authors.initials: ES
authors.lastname: Lichtenberg
authors.forename: Carol
authors.initials: C
authors.lastname: Ball
authors.forename: Gillian
authors.initials: G
authors.lastname: Dean
authors.forename: Daniel
authors.initials: D
authors.lastname: Sacks
authors.forename: William A
authors.initials: WA
authors.lastname: Crowden
authors.forename: Yael
authors.initials: Y
authors.lastname: Swica
mesh_terms: D000020:Abortifacient Agents, Nonsteroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000021:Abortifacient Agents, Steroidal / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D000028:Abortion, Induced / Q000379:methods*; D000282:Administration, Intravaginal; D000293:Adolescent; D000328:Adult; D000554:Ambulatory Care Facilities; D004359:Drug Therapy, Combination; D005260:Female; D005865:Gestational Age; D006801:Humans; D015735:Mifepristone / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D016595:Misoprostol / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D010045:Outpatients; D010342:Patient Acceptance of Health Care; D011247:Pregnancy; D011446:Prospective Studies; D013997:Time Factors; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000020:Abortifacient Agents, Nonsteroidal; D000021:Abortifacient Agents, Steroidal; D016595:Misoprostol; D015735:Mifepristone